Subject to approval of a listing application, and a successful completion of the IPO, Ultimovacs ASA is expected to be admitted to listing and commence trading on Oslo Stock Exchange on or about 3 June 2019. The Prospectus and the application form for the retail offering is published today (21.05.2019) and is, subject to regulatory restrictions in certain jurisdictions, be available at www.dnb.no/emisjoner from the commencement of the bookbuilding period and the application period.
Initial Public Offering
Technology
Ultimovacs is developing a universal cancer vaccine applicable across a broad spectrum of cancer types.
Clinical studies
Lead product tested in three clinical trials, strong results justifies the initiation of a registration trial.